Harjinder Chowdhary, MD
Rheumatology · Norwich, CTNPI 1205942836
Payments from drug & device makers
Across 702 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Mallinckrodt Hospital Products Inc.$1K
- AbbVie$1K
- Johnson & Johnson$1K
- Pfizer$935
- UCB, Inc.$800
- plus $5K from 32 others
What the payments were for
- Food & beverage$12,62095%
- Education$6405%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 120 | $2,206 |
| Mallinckrodt Hospital Products Inc. | 64 | $1,458 |
| AbbVie | 83 | $1,409 |
| Johnson & Johnson | 79 | $1,324 |
| Pfizer | 60 | $935 |
| UCB, Inc. | 40 | $800 |
| AstraZeneca(2 entities) | 28 | $642 |
| GSK | 30 | $536 |
| Novartis | 24 | $536 |
| Boehringer Ingelheim | 19 | $443 |
| Genentech USA, Inc. | 19 | $396 |
| E.r. Squibb & Sons, L.L.C. | 23 | $388 |
| Sobi, Inc | 11 | $237 |
| Lilly USA, LLC | 14 | $231 |
| Aurinia Pharma U.S., Inc. | 8 | $186 |
| Organon | 8 | $143 |
| Mallinckrodt Enterprises LLC | 12 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $118 |
| ANI Pharmaceuticals, Inc. | 5 | $110 |
| Actelion Pharmaceuticals US, Inc. | 3 | $103 |
| Hikma Pharmaceuticals USA | 5 | $95 |
| Sanofi | 5 | $95 |
| Radius Health, Inc. | 4 | $94 |
| Octapharma USA, Inc. | 4 | $86 |
| Fresenius Kabi USA, LLC | 4 | $78 |
| Merck | 4 | $63 |
| Gilead | 4 | $61 |
| Pharming Healthcare, Inc. | 2 | $51 |
| Medexus Pharma, Inc. | 3 | $44 |
| Ultragenyx Pharmaceutical Inc. | 2 | $43 |
| Alnylam Pharmaceuticals Inc. | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Shorla Oncology Inc. | 1 | $32 |
| Sandoz | 2 | $29 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Avion Pharmaceuticals | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Strensiq$130
How this compares
$13,260 in reported general payments places this provider in the 75th percentile of 118 rheumatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 92 | $772,448 |
| Orencia ClickjectAbatacept | 93 | $654,235 |
| OtezlaApremilast | 78 | $389,438 |
| Humira(Cf) PenAdalimumab | 44 | $348,683 |
| Humira PenAdalimumab | 29 | $243,181 |
| RinvoqUpadacitinib | 31 | $238,489 |
| KevzaraSarilumab | 43 | $202,278 |
| OrenciaAbatacept | 27 | $183,426 |
| Xeljanz XrTofacitinib Citrate | 29 | $159,627 |
| Actemra ActpenTocilizumab | 38 | $113,998 |
| Cosentyx (2 Syringes)Secukinumab | 13 | $110,939 |
| EnbrelEtanercept | 13 | $94,583 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 22 | $76,193 |
| XeljanzTofacitinib Citrate | 11 | $66,357 |
| PlaquenilHydroxychloroquine Sulfate | 20 | $35,055 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla, Enbrel | $2,206 | $484,02191 claims |
| AbbVieRinvoq | $1,409 | $238,48931 claims |
| SanofiKevzara | $95 | $202,27843 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $388 | $183,42627 claims |
| NovartisCosentyx (2 Syringes) | $536 | $110,93913 claims |
| PfizerXeljanz | $935 | $66,35711 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $23 | $1,64752 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 118 rheumatology providers in Connecticut.
Other rheumatology in Norwich
- Jackilyn AnnelliNorwich$3K
- Sandeep VarmaNorwich$3K
- Fotios KoumpourasNorth Haven$1.5M
- Kenneth MillerDanbury$930K
- Monique HinchcliffNorth Haven$883K
- Robert SchoenGuilford$638K
- Stuart NovackNorwalk$507K
- Bret SohnStamford$460K
- Geoffrey GladsteinTrumbull$452K
- John MagaldiTorrington$451K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.